Previous 10 | Next 10 |
Gainers: Apyx Medical (APYX) +39%. Enochian Biosciences (ENOB) +17%. Concert Pharmaceuticals (CNCE) +14%. GeoVax Labs (GOVX) +14%. Liquidia (LQDA) +13%. Losers: NRx Pharmaceuticals (NRXP) -57%. Avadel Pharmaceuticals (AVDL) -44%. Nurix Therape...
The shares of NRx Pharmaceuticals (NASDAQ:NRXP) have lost ~39% in the pre-market Thursday after the Wilmington, Delaware-based pharmaceutical company said that its ACTIV-3b study for experimental COVID-19 drug Zyesami (aviptadil) did not reach key goals. The trial sponsored by Natio...
NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19 PR Newswire Based on a review of nearly 75% of the target enrollment of 640 patients, most of wh...
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference PR Newswire Company to Present Corporate Update During Investor...
NRx Pharmaceuticals press release (NASDAQ:NRXP): Q1 GAAP EPS of -$0.21. As of March 31, 2022, cash was $40.2 million compared to $27.6 million as of December 31, 2021. NRx Pharmaceuticals believes it has sufficient cash to support operations for at least the next 12 months. For further deta...
NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results PR Newswire Company to Host Conference Call and Webcast May 16, 2022 , at 8:30am ET RADNOR, Pa. , May 16, 2022 /PRNewswire/ -- NRx Pharmaceutical...
NRx Pharma (NASDAQ:NRXP) is trading 6.8% higher premarket after the company said on Thursday it had enrolled the first patient in one of the two psychiatry phase 2 studies that it plans to initiate this year, testing its drug NRX-101. The first trial will study patients with bi...
NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality PR Newswire NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial i...
NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022 PR Newswire --Company to Host Conference Call May 16, 2022 , at 8:30AM ET -- RADNOR, Pa. , May 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into NRx Pharmaceuticals (NasdaqGM: NRXP) and provides the following update. In June 2021, ...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...